Company Overview and News

4
Sliding Emerging Markets Bear Brunt of Angst Over Trade, OPEC - Bloomberg

2h bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
MSCI

4
Global stocks, oil suffer as US-China trade spat heats up

3h malaymail
LONDON, June 18 — Global stocks slid today and US oil prices slumped after US President Donald Trump announced tariffs on Chinese goods and Beijing responded with similar measures in an escalating trade dispute.
MSCI

64
Singapore Exchange India Futures to continue as dispute drags on

4h theedgemarkets
SINGAPORE (June 18): Singapore Exchange Ltd and National Stock Exchange of India Ltd will remain partners for a little longer than both anticipated.
JBK GS.PRICL GSC SPXCF TFG GS.PRB GS.PRA S68 GSJ GS.PRJ GS.PRI GS SPXCY GLSSP GS.PRD GS.PRC GJS GS.PRN MSCI GS.PRK

4
NZ sharemarket on top of the world - and beating the Aussies

22h nzherald.co.nz
New Zealand stock exchange returns are topping the world - and resoundingly thrashing the ASX 200 across the Tasman.
MSCI

16
From Well To Pump: Opportunities Within The Energy Sector

2018-06-15 seekingalpha
The price of crude oil has risen sharply over the last 12 months, outpacing shares of energy companies.
JPXGY OSCUF WTI LSE DTK TRI FILL 8697 MSCI

4
MSCI / MSCI, Inc. null

2018-06-14 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @(" @#0HR M,B P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X-"],(#8X+TQE;F=T M:" V,B]3(#,X/CYS=')E86T-"FC>[email protected][email protected]
MSCI

4
Mobius Not Convinced by Saudi Stocks Poised for Status Upgrade

2018-06-13 theedgemarkets
(June 14): As Saudi Arabia stands poised to win emerging-market status, one of the best-known developing-nation investors says he isn’t completely convinced the kingdom’s stocks are a good option.
MSCI

22
Investments Pour out of EM Funds, but Why? | Chief Investment Officer

2018-06-13 ai-cio
The end of the emerging market boom doesn’t mean that these stocks are in a death spiral.
BNPZY MS.PRI MS.PRK BNPQY MS.PRE MS.PRF MS.PRG BNPQF MS MS.PRA MSCI

4
World Leaders Pose And Strut But Will Likely Cooperate In The End

2018-06-13 seekingalpha
As we went to press, President Trump was meeting North Korean Supreme Leader Kim Jong-un in Singapore. Over the weekend, there was a lot of outraged reaction by G7 leaders to President Trump’s appearance at the G7 meeting, but I expect that most countries will follow China, which offered last week to purchase nearly $70 billion of U.S. farm, manufacturing, and energy products in order to keep the trade flowing.
MSCI

4
Comment: Five steps to stronger capital markets

2018-06-10 nzherald.co.nz
If the New Zealand economy were a human body, then we can think of capital as the oxygen required to sustain life.
NZSTY NZSTF MSCI

4
Chinese Stocks Have Been Money-Losing Bets This Year - WSJ

2018-06-08 wsj
Chinese markets have dropped so far this year, despite the fact that global index provider MSCI Inc. MSCI -0.14% added more than 200 of the country’s stocks to its widely tracked emerging-market index at the start of June—an event analysts said would spark an influx of foreign cash into China.
HHPG HHPD MSCI

130
ESG Funds: Impact And Alpha

2018-06-06 seekingalpha
This article originally appeared in the June issue of Wealth Management magazine and online at Brad Zigler.
SNSR AND TXN LIT KRMA BFIT GXG SIL ADP GXF ESG CHII ACTX CHIE GOEX FINX CHIX 3772 MSCI SRET BOTZ CATH ESGU GURX GURI DSI ALUM MILN CJHIQ URA LNGR ADPVV TROW COPX ABBV QQQC GURU

12
Valuation Dashboard: Financials And Real Estate - Update

2018-06-06 seekingalpha
This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages.
RJD HST SYF RJF MSCI

4
China beer stock bulls pine for vindication on valuations

2018-06-06 thestar.com.my
While the sector lags behind global brewers in operating margins and earnings growth, the companies trade at a premium that outstrips their peer average by several times – thanks in part to the US-China trade tension that recently sparked a wave of demand for shares of domestically focused sectors from beverage to healthcare.
0168 MSCI

23
Janitors Are Becoming Millionaires Thanks to This Stock’s 9,500% Rally - Bloomberg

2018-06-05 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
DSLV VIIX DGLD CSSLF VIIZ NFLX CS CSGKF UGLD ZIV USLV TVIX MSCI XIV

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

10h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to MSCI / MSCI, Inc. on message board site Silicon Investor.

EWJ : ISHARES MSCI JAPAN INDEX FD (AMEX)
CUSIP: 55354G100